Efficacy of ACT in Patients Scheduled for Lumbar Spine Surgery (SPINE-ACT)

Efficacy of Acceptance and Commitment Therapy in Patients Scheduled for Lumbar Spine Surgery (SPINE-ACT Project)

Objectives: (1) To analyze the effectiveness of adding a group-based form of Acceptance and Commitment Therapy (ACT) to the treatment as usual (TAU) for preoperative patients diagnosed with degenerative lumbar pathology plus psychosocial risk factors related to post-surgical chronic pain at baseline and after psychological treatment. (2) To examine the effectiveness of ACT on the improvement of pain interference, pain-related and behavioral variables in degenerative lumbar pathology preoperative patients after lumbar spine surgery in comparison with TAU. (3) To measure the proximal and distal effects of ACT in preoperative patients with degenerative lumbar pathology who had the surgery after ACT program completion in comparison with proximal and distal TAU surgery effects on pain related variables.

Method: A 12-month randomized controlled trial (RCT) will be conducted at Hospital del Mar (Barcelona). Only those preoperative degenerative lumbar pathology patients with psychosocial risk factors for chronic post-surgical pain will be randomized to pre-surgical ACT group or to TAU. Evaluations will be completed before treatment (baseline), after ACT therapy (3 months), a first follow-up (6 months from baseline alias 3 months after surgery), second follow-up (9 months from baseline alias 6 months after surgery), and final follow-up (15 months from baseline alias 12 months from surgery).

Participants: 80 adult preoperative patients with degenerative lumbar pathology plus psychosocial risk factors related to post-surgical chronic pain will be randomly assigned to two arms: ACT + TAU vs TAU.

Primary outcome: Pain interference. Secondary outcomes: pain intensity, pain catastrophising, pain acceptance, pain disability, kinesiophobia, depression symptoms, anxiety symptoms, psychological flexibility, and quality of life.

Main statistical analyses: Intention-to-Treat analyses that will include all participants who undergo random allocation, using multiple imputation to replace missing values. General linear mixed-effects models will be performed using Restricted Maximum Likelihood to estimate the parameters. Calculation of between-groups effect sizes using Cohen's d and of the number-needed-to-treat.

Study Overview

• Status: Recruiting
• Conditions: Randomized Controlled Trial
• Intervention / Treatment: Behavioral: Acceptance and Commitment Therapy (ACT); Behavioral: Treatment as Usual (TAU)

Detailed Description

The Spine-ACT project's main objective is to determine the effectiveness of adding to the standard care (TAU) of preoperative patients with degenerative lumbar pathology plus psychosocial risk factors related to post-surgical chronic pain, a group-based form of ACT. In this regard, assessing patients' results after surgery at proximal or distal improvement on pain-related variables compared with TAU surgery patients would be addressed. The Spine-ACT project will assess the usefulness of ACT therapy applied before surgery to improve pain-related variables and quality of life in preoperative degenerative lumbar pathology patients with psychosocial risk factors of developing chronic or post-surgical pain. This project will significantly expand the limited knowledge available about preoperative pain-related improvement through ACT therapy and how this psychological therapy could prevent post-surgical chronic pain. Thus, it is expected that ACT therapy can improve the various pain-related and quality-of-life variables in developing chronic pain in preoperative patients diagnosed with degenerative lumbar pathology plus psychosocial risk factors of post-surgical chronic pain.

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Juan Ramón Castaño-Asins, MD; Phone Number: 3175 +34932483000; Email: jrcastano@psmar.cat
• Study Contact Backup: Name: Ariadna Colomer-Carbonell, MSc; Phone Number: 2546 +34936406350; Email: ariadna.colomer@sjd.es

Study Locations

• Spain
  • Barcelona, Spain, 08003
    • Recruiting
    • Parc Salut Mar
    • Contact: Juan Ramón Castaño-Asins, MD; Phone Number: 3175 +34932483000; Email: jrcastano@psmar.cat

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age 18- 80 years
• Possess an adequate understanding of Spanish or Catalan

• Meet the diagnostic criteria for lumbar pain/degenerative lumbar pathology candidates for surgical treatment.

  • Diagnoses:

    1. Lumbar canal stenosis.
    2. Foraminal stenosis.
    3. Lumbar spondylolisthesis.
    4. Lumbar degenerative disc disease.
    5. Degenerative scoliosis.
    6. Lumbar kyphosis.
  • Procedures:

Laminectomy. Foraminoplasty. Laminectomy and posterior arthrodesis. previous arthrodesis.

• Presence of psychosocial risk factors for chronic post-surgical pain:

  • Mild-moderate anxiety/depression symptoms (HADS hospital anxiety and depression sub-scales≥11, see measurement instruments section) and/or
  • Presence of catastrophizing (PCS catastrophizing scale (0-52) ≥24, see measurement instruments section), and/or
  • Kinesiophobia base ≥27, see measurement instruments section)
• Have an internet connection on a mobile phone, tablet, computer, etc. to be able to carry out group psychological therapy online.
• Give authorization by signing an informed consent

Exclusion Criteria:

• Cognitive impairment that in the clinician's judgment prevents you from participating in therapy
• Presenting chronic pain not related to the diagnosis of low back pain that is a candidate for surgical treatment
• NOT present psychosocial risk factors for chronic post-surgical pain (see inclusion criteria: anxiety, catastrophizing, depression, kinesiophobia)
• Patients in litigation or who are pending legal claims for compensation
• Severe or decompensated psychiatric disorder (depression, schizophrenia, bipolar disorder, personality disorder) that in the clinician's judgment prevents you from participating in therapy
• Suicidal ideation
• Consumption of toxic substances in abuse/dependence, except for smoking
• Patients with a language barrier (Spanish/Catalan)
• Patients who do not authorize it voluntarily and do not want to participate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TAU + Acceptance and Commitment Therapy (ACT); This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.	Behavioral: Acceptance and Commitment Therapy (ACT); Group treatment protocol of 8 weeks of 90 minutes sessions Session 1: Presentation of the general ACT therapy concept. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis third Session 5: Values and feelings. Session 6: Drink one direction. Session 7: Dare and change. Session 8: Ready to act with ACT. Treatment as usual (TAU) Standard pharmacological treatment for patients with chronic pain.
Active Comparator: Treatment as Usual (TAU); Standard care. The standard treatment would generally be pharmacological to address chronic pain, adjusted to the symptomatic profile of each patient.	Behavioral: Treatment as Usual (TAU); Standard pharmacological treatment for patients with chronic pain

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Brief Pain Inventory (BPI)	It is a questionnaire that assesses chronic pain in a multidimensional way. It provides information on the intensity of the pain and on the degree of interference in the functioning and daily activities of the patients. It has 11 items. The first 4 items evaluate the intensity of pain in the last 24 hours. Subsequently, 7 items that report the degree of involvement of chronic pain in various areas of the person's functioning are evaluated. The higher the score in the areas of the questionnaire, the greater the intensity of perceived pain, as well as the greater degree of involvement of chronic pain in the functioning of the person in the various areas explored	Through study completion, an average of 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hospital Anxiety and Depression Scale (HADS)	A scale of 14 items was created to assess symptoms of anxiety and depression. The total score ranges from 0 to 42, and each subscale (HADS-Anxiety and HADS-Depression) includes 7 items with scores ranging from 0 to 21. Higher scores indicate higher symptom severity.	Through study completion, an average of 2 years
Pain Catastrophising Scale (PCS)	The scale of 13 items comprises three dimensions: rumination over pain, magnification of pain, and helplessness in the ace of pain symptoms. The PCS total score and subscale scores are computed as the sum of ratings for each item. This study used the total score, which can vary from 0 to 52 with higher scores indicating greater pain catastrophizing.	Through study completion, an average of 2 years
Psychological Inflexibility in Pain Scale (PIPS)	12-item scale that assesses psychological inflexibility in patients with pain and includes two factors: avoidance and cognitive fusion with pain. For this study, only the total score is used; it ranges from 12 to 84, with higher scores indicating higher level of psychological inflexibility.	Through study completion, an average of 2 years
Tampa Kinesiophobia Scale (TSK-11SV)	It is a questionnaire that allows us to measure the fear of moving or being injured/(re)injured, in patients with pain. The final score can be at least 11 and a maximum of 44 points; the higher the score, the higher the degree of kinesiophobia. It is considered that a score ≥18 is already indicative of a fear of movement, which increases in severity as the score increases.	Through study completion, an average of 2 years
Chronic Pain Acceptance Questionnaire (CPAQ-20)	It consists of 20 items organized in a factorial structure of two subscales. The maximum possible total score is 120, so that higher scores indicate a higher level of the acceptance construct in the process.	Through study completion, an average of 2 years
Short Form 12 Health Survey (SF-12)	This scale includes measures of health-related quality of life. It is made up of a subset of 12 items, with 8 dimensions, and 2 summative components (physical and mental). The items are coded, added, and transformed into a scale that ranges from 0 (the worst state of health for that dimension) to 100 (the best state of health).	Through study completion, an average of 2 years
Oswestry Low Back Pain Disability Scale (OLBPDQ)	The scale consists of 10 questions with 6 response possibilities each. The total score, expressed as a percentage (0 to 100%), is obtained as the sum of the estimates for each element divided by the maximum possible score multiplied by 100. High values describe greater functional limitations.	Through study completion, an average of 2 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Socio-demographic questionnaire	Gender, date of birth, marital status, living arrangements, educational level and employ-ment status.	Baseline

Collaborators and Investigators

• Sponsor: Parc de Salut Mar
• Investigators: Study Director: Antonio Montes-Pérez, PhD, Parc Salut Mar; Study Director: Víctor Pérez-Solà, PhD, Parc Salut Mar; Study Chair: Luis Miguel Martín-López, PhD, Parc Salut Mar; Study Director: Alejandro Del Arco-Churruca, PhD, Parc Salut Mar; Study Chair: Jesús Lafuente Baraza, PhD, Parc Salut Mar; Study Director: Juan V. Luciano, PhD, Parc Sanitari Sant Joan de Déu; Principal Investigator: Juan Ramón Castaño-Asins, MD, Parc Salut Mar

Study record dates

Study Major Dates

• Study Start (Actual): November 26, 2021
• Primary Completion (Anticipated): December 31, 2023
• Study Completion (Anticipated): December 31, 2024

Study Registration Dates

• First Submitted: November 21, 2022
• First Submitted That Met QC Criteria: November 30, 2022
• First Posted (Actual): December 1, 2022

Study Record Updates

• Last Update Posted (Estimate): December 7, 2022
• Last Update Submitted That Met QC Criteria: December 5, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: 2021/9998/I

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No